Elinzanetant, sold under the brand name Lynkuet, is a medication used for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause. It is taken orally.
The drug acts as a selective neurokinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonist.
Elinzanetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Elinzanetant has been found to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women.
Elinzanetant was developed by Bayer Healthcare.
In September 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Lynkuet, intended for the treatment of moderate to severe vasomotor symptoms (hot flushes). The applicant for this medicinal product is Bayer AG. Elinzanetant was authorized for medical use in the European Union in November 2025.
Lynkuet was approved for medical use in the United States in October 2025.
Elinzanetant is the International Nonproprietary Name (INN).
Elinzanetant is sold under the brand name Lynkuet.
In addition to approval for vasomotor symptoms, elinzanetant is under development for the treatment of sleep disorders. It is in phase 2 clinical trials for this indication. The drug was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.